Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue
Top Cited Papers
- 7 September 2015
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 78 (5), 787-800
- https://doi.org/10.1002/ana.24517
Abstract
Objective To examine region‐ and substrate‐specific autoradiographic and in vitro binding patterns of positron emission tomography tracer [F‐18]‐AV‐1451 (previously known as T807), tailored to allow in vivo detection of paired helical filament‐tau–containing lesions, and to determine whether there is off‐target binding to other amyloid/non‐amyloid proteins. Methods We applied [F‐18]‐AV‐1451 phosphor screen autoradiography, [F‐18]‐AV‐1451 nuclear emulsion autoradiography, and [H‐3]‐AV‐1451 in vitro binding assays to the study of postmortem samples from patients with a definite pathological diagnosis of Alzheimer disease, frontotemporal lobar degeneration–tau, frontotemporal lobar degeneration–transactive response DNA binding protein 43 (TDP‐43), progressive supranuclear palsy, corticobasal degeneration, dementia with Lewy bodies, multiple system atrophy, cerebral amyloid angiopathy and elderly controls free of pathology. Results Our data suggest that [F‐18]‐AV‐1451 strongly binds to tau lesions primarily made of paired helical filaments in Alzheimer brains (eg, intraneuronal and extraneuronal tangles and dystrophic neurites), but does not seem to bind to a significant extent to neuronal and glial inclusions mainly composed of straight tau filaments in non‐Alzheimer tauopathy brains or to lesions containing β‐amyloid, α‐synuclein, or TDP‐43. [F‐18]‐AV‐1451 off‐target binding to neuromelanin‐ and melanin‐containing cells and, to a lesser extent, to brain hemorrhagic lesions was identified. Interpretation Our data suggest that [F‐18]‐AV‐1451 holds promise as a surrogate marker for the detection of brain tau pathology in the form of tangles and paired helical filament‐tau–containing neurites in Alzheimer brains but also point to its relatively lower affinity for lesions primarily made of straight tau filaments in non‐Alzheimer tauopathy cases and to the existence of some [F‐18]‐AV‐1451 off‐target binding. These findings provide important insights for interpreting in vivo patterns of [F‐18]‐AV‐1451 retention. Ann Neurol 2015 Ann Neurol 2015;78:Ann Neurol 2015;78:679–696Keywords
Funding Information
- NIH (U01NS086659, R01MH100350)
- Harvard NeuroDiscovery Center (Boston, MA)
- NIH National Institute on Aging (AG005133, AG025204, AG005133, AG025204, AG025204, AG014449, AG005134)
This publication has 25 references indexed in Scilit:
- Clinicopathologic assessment and imaging of tauopathies in neurodegenerative dementiasAlzheimer's Research & Therapy, 2014
- Second consensus statement on the diagnosis of multiple system atrophyNeurology, 2008
- Twenty-first century brain banking. Processing brains for research: the Columbia University methodsActa Neuropathologica, 2007
- Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar DegenerationActa Neuropathologica, 2007
- Region-specific Dissociation of Neuronal Loss and Neurofibrillary Pathology in a Mouse Model of TauopathyThe American Journal of Pathology, 2006
- Tau Suppression in a Neurodegenerative Mouse Model Improves Memory FunctionScience, 2005
- The Neuropathological Spectrum of Neurodegenerative TauopathiesIUBMB Life, 2003
- Pathogenic Effects of D23N Iowa Mutant Amyloid β-ProteinJournal of Biological Chemistry, 2001
- Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB)Neurology, 1996
- HIGH-RESOLUTION AUTORADIOGRAPHYThe Journal of cell biology, 1962